These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23226096)

  • 1. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
    Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
    Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab.
    Wang A; Cui M; Qu H; Di J; Wang Z; Xing J; Wu F; Wu W; Wang X; Shen L; Jiang B; Su X
    Oncotarget; 2016 Nov; 7(46):75293-75306. PubMed ID: 27659529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
    Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
    Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
    Montagut C; Dalmases A; Bellosillo B; Crespo M; Pairet S; Iglesias M; Salido M; Gallen M; Marsters S; Tsai SP; Minoche A; Seshagiri S; Serrano S; Himmelbauer H; Bellmunt J; Rovira A; Settleman J; Bosch F; Albanell J
    Nat Med; 2012 Jan; 18(2):221-3. PubMed ID: 22270724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
    Koefoed K; Steinaa L; Søderberg JN; Kjær I; Jacobsen HJ; Meijer PJ; Haurum JS; Jensen A; Kragh M; Andersen PS; Pedersen MW
    MAbs; 2011; 3(6):584-95. PubMed ID: 22123060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
    Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
    J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.
    Braig F; März M; Schieferdecker A; Schulte A; Voigt M; Stein A; Grob T; Alawi M; Indenbirken D; Kriegs M; Engel E; Vanhoefer U; Grundhoff A; Loges S; Riecken K; Fehse B; Bokemeyer C; Binder M
    Oncotarget; 2015 May; 6(14):12035-47. PubMed ID: 26059438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
    Kim N; Cho D; Kim H; Kim S; Cha YJ; Greulich H; Bass A; Cho HS; Cho J
    Int J Cancer; 2020 Apr; 146(8):2194-2200. PubMed ID: 31290142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagents.
    Park NJ; Wang X; Diaz A; Goos-Root DM; Bock C; Vaught JD; Sun W; Strom CM
    PLoS One; 2013; 8(8):e71703. PubMed ID: 23990977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
    Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
    Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
    Price T; Ang A; Boedigheimer M; Kim TW; Li J; Cascinu S; Ruff P; Satya Suresh A; Thomas A; Tjulandin S; Peeters M
    Cancer Biol Ther; 2020 Oct; 21(10):891-898. PubMed ID: 33026965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance.
    Bagchi A; Haidar JN; Eastman SW; Vieth M; Topper M; Iacolina MD; Walker JM; Forest A; Shen Y; Novosiadly RD; Ferguson KM
    Mol Cancer Ther; 2018 Feb; 17(2):521-531. PubMed ID: 29158469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combinatorial mutagenesis approach for functional epitope mapping on phage-displayed target antigen: application to antibodies against epidermal growth factor.
    Infante YC; Pupo A; Rojas G
    MAbs; 2014; 6(3):637-48. PubMed ID: 24589624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance.
    Tabasinezhad M; Omidinia E; Talebkhan Y; Omrani MD; Mahboudi F; Ghaedi H; Wenzel W
    Proteins; 2020 Jan; 88(1):3-14. PubMed ID: 31228284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
    Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
    Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.
    Tundidor Y; García-Hernández CP; Pupo A; Cabrera Infante Y; Rojas G
    MAbs; 2014; 6(4):1013-25. PubMed ID: 24759767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
    Makabe K; Yokoyama T; Uehara S; Uchikubo-Kamo T; Shirouzu M; Kimura K; Tsumoto K; Asano R; Tanaka Y; Kumagai I
    Sci Rep; 2021 Mar; 11(1):5790. PubMed ID: 33707468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
    Li S; Kussie P; Ferguson KM
    Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.